Tiny-Ad-8280
🚨 25¢ Stock. Stage 4 Cancer. 36+ Months Cancer-Free. Do the Math. 🚨
Let me tell you a story that shouldn’t be real — but is.
A story about terminal cancer patients who were supposed to be dead by now…
But instead, they’re alive. And cancer-free.
The company? CytoDyn ($CYDY) — a tiny biotech stock trading at just 25 cents.
The drug? Leronlimab.
And the data it’s about to present on May 15th at Europe’s biggest cancer conference (ESMO) might change everything.
Here’s what every investor — and every human — should know:
🧬 First, What Is Stage 4 mTNBC?
Let’s break that down:
Stage 4 = metastatic cancer — it’s spread from the breast to other organs like the brain, lungs, or liver.
mTNBC = metastatic triple-negative breast cancer — the most aggressive, deadliest form. It doesn’t respond to hormone therapy or HER2-targeted drugs. There’s no known cure.
Once you reach stage 4 mTNBC, the median survival is less than 12 months.
Let’s be real: Most patients don’t live a year.
🧪 Then Came Leronlimab
CytoDyn ran a small trial with 30 patients who already failed other treatments.
Many had cancer in their brain, liver, and lungs. They were out of options.
Here’s what happened:
All 30 patients (mixed doses):
Median overall survival (OS): 6.6 months
Median progression-free survival (PFS): 3.8 months
🧠 PFS = how long the cancer stays stable before it gets worse.
OS = how long people stay alive.
But then they zoomed in on 19 patients who got higher doses (525–700mg):
Median OS jumped to 12+ months
Median PFS rose to 6.1 months
❗️12+ means they were still alive at the time — they couldn’t even finish calculating it.
💥 The Bombshell: 36+ Months Cancer-Free
Fast forward to 2025.
CytoDyn got follow-up records after resolving a dispute with their old CRO (Amarex). What they found?
“A small group of patients… survived more than 36 months after receiving Leronlimab… and currently identify as having no evidence of ongoing disease.”
Read that again.
These were terminal cancer patients — not just surviving, but alive three years later with zero signs of cancer.
Not "slowed down." Not "in remission."
🎯 Cancer. Free.
🤔 What’s a “Functional Cure”?
It means the patient isn’t just surviving — they’re living a normal life, no signs of cancer, no progression.
In stage 4 mTNBC, that’s never been done before.
This isn’t about managing cancer. It’s about potentially beating it.
🥊 How Does It Compare to Trodelvy?
Trodelvy is another mTNBC drug.
Gilead bought it for $21 billion in 2020 after it showed:
Median OS: 11.8 months
PFS: 4.8 months
That was considered a major success — and it should’ve been.
But Leronlimab?
Has patients alive 36+ months
With no signs of disease
And median OS still growing
It’s not just a different league — it’s a different universe.
🧠 Why May 15th Matters
That’s when the world sees this data.
At ESMO Breast Cancer 2025 in Munich.
Dr. Richard Pestell — world-class oncologist (ex-J&J and Pfizer) — is presenting it.
And yeah, it’s a “poster” presentation.
But so was Trodelvy’s first public showing.
👉 Poster sessions are where Big Pharma scouts its next buyout.
💡 TL;DR — Send This to Your Group Chat
Stage 4 mTNBC = death sentence. Median survival is <12 months.
Leronlimab = 36+ month survival. Cancer-free. Possibly a functional cure.
Trodelvy got a $21B deal with 12-month survival.
Leronlimab’s median OS can’t even be calculated yet… because patients are still alive.
This gets revealed to the world on May 15th.
The stock? Still trading for just $0.25.
🔥 Final Thought
If this data holds up, it’s not just the biotech story of the decade…
💣 It might be one of the biggest medical breakthroughs in human history.
Because for the first time ever, we might be seeing a drug that functionally cures terminal cancer.
And it’s hidden inside a penny stock almost nobody is watching.
May 15th will tell the world.
Until then… do your homework.
AI
